Mark Payton

Oxxon Therapeutics, Inc. develops and manufactures antigen-specific immunotherapies to treat patients with chronic infectious diseases and cancer. The company has three development programs in hepatitis, melanoma, and HIV. Oxxon Therapeutics was founded in 1999 by Dr. Joerg Schneider and is located at Oxford, UK.

West Midlands Enterprise Ltd. operates as an alternative investment manager. It provides IT and business consultancy services. The company was founded in 1982 and is headquartered in Solihull, the United Kingdom.

Oxford University Innovation Ltd (Oxford University Innovation) is a venture capital subsidiary of University of Oxford founded in 1987 and spun out in 2010. The firm is headquartered in London, United Kingdom.

Hybrid is an Oxford Biotechnology Company focused on revolutionizing viral vaccines with its patented vaccine delivery technologies. Hybrid has an established and well equipped laboratory located at Cherwell Innovation Centre in Oxford shire, which houses both its corporate research facility and contract research services. Using a mixed product and platform business model it is developing its in-house lead products towards phase I/II proof of concept clinical trials as well as furthering its partnerships with leading pharmaceutical and biotechnology companies. Hybrid's experienced scientific and management team has reached this late stage of development through a highly efficient use of grant funding and revenues, together with minimal seed funding. With its unparalleled expertise in the field of viral steal thing technologies, The firm is also able to offer general and bespoke virology services, including high-quality adenovirus production and purification. Hybrid BioSystems uses iLabber electronic lab books for maximum IP protection and secure data storage.

Mercia Fund Management Ltd. (Mercia Fund) is a private equity subsidiary of Mercia Asset Management Plc founded in 1999 by Mark Andrew Payton, Timothy R. Hazell and Everard Mascarenhas. The firm is headquartered in Warwickshire, Great Britain.

nanoTherics Ltd. develops and manufactures magnetic nanoparticle-based products. Its product range includes devices and reagents for magnet assisted transfection and delivery of biomaterials into cells for the life science research and development market as well as products for nanoparticle heating applications. The company was founded by Jon Dobson and Neil Farrow in 2007 and is headquartered in Newcastle-under-Lyme, the United Kingdom.

PolyTherics Ltd. develops biomedical polymers for therapeutic applications. The company was founded by Antony Godwin, Sunil Shaunak and Steve Brocchini in 2001 and is headquartered in Babraham, the United Kingdom.

Akamis Bio Ltd. operates as a biotechnology company which develops novel therapeutics that addresses cancer and other clinically unmet diseases. Its products include Enadenotucirev, Espindolol and AbEnAd. The firm also develops treatments based upon the research phase vaccine platform PolySTAR, which combines recombinant viral vectors with polymers to shield them from the immune system, and the research phase adjuvant and immunotherapeutic platform PolyMAP, which combines polymers with synthetic adjuvants to significantly enhance the effectiveness of vaccines. The company was founded by Andrew Justin Stewart Coats and Stefan D. Anker on November 17, 2006 and is headquartered in Abingdon, the United Kingdom.